Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677158 | 1.00 | ATM (0.41) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL16300602 | 0.85 | ATM (0.34) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL1081071 | 0.85 | ATM (0.31) | ATM | |
| SCHEMBL16300595 | 0.85 | ATM (0.34) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL1025789 | 0.85 | ATM (0.31) | ATM | |
| SCHEMBL16349156 | 0.85 | ATM (0.34) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL4258841 | 0.81 | ATM (0.42) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL4254075 | 0.81 | ATM (0.42) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL4251630 | 0.81 | ATM (0.42) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL4258297 | 0.81 | ATM (0.42) | ATMPOLBCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885POLB 2801/4885CHRM2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.